Fine-tuning the Neutrophilic Response to Pneumonia

微调中性粒细胞对肺炎的反应

基本信息

项目摘要

Project Summary/Abstract The lung is a portal of entry for a variety of pathogenic organisms that may cause pneumonia or even the acute respiratory distress syndrome (ARDS), which is a life-threatening syndrome that has no specific treatments except for the provision of gentle mechanical ventilation and supportive care. The neutrophil is a critical cellular mediator of the early immune response to pathogenic lung infections, but an overly exuberant neutrophil response may cause collateral damage to the lung and lead to acute lung injury. In this application, a new function of neutrophils, the release of neutrophil extracellular traps (NETs), will be investigated in mouse models of acute lung infection. NETs are composed of extracellular chromatin decorated with neutrophil granular proteins and have been proposed to serve an important role in the trapping and killing of bacteria and other pathogens. However, we propose that NETs are toxic to adjacent cells and are on balance a maladaptive and dispensible host response in pneumonia and acute lung injury. Aim 1 of this application will investigate the role of NETs in mouse models of bacterial and viral pneumonia using novel techniques to visualize and quantify NETs. We will also test the role of lipoxin mediators signaling through Fpr2 on neutrophils in regulating NET production and the progression to acute lung injury. Aim 2 will test the role of DNase1 in regulating the degradation of NETs in the lung and the important effects of DNase1 treatment on the containment of infection and preservation of the lung barrier. In translational studies, Aim 2 will also use biological samples from critically ill patients with severe infections to test if NETs and DNase1 bioactivity (a) predict the progression to ARDS or (b) are associated with poor clinical outcomes in ARDS. The factors that determine whether a localized lung infection progresses to acute lung injury are not known, but this application proposes that NETs are critical mediators in this process and targetable. Our studies using live bacterial and viral infections, novel approaches to visualize acute lung inflammation and injury, and NETs, pharmacologic and genetic approaches to neutralize NETs, and translational studies to complement our mouse models, are well-positioned to provide definitive evidence on the in vivo significance of NETs, and to position NETs as a novel target for the treatment of pathogen-induced lung injury.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK ROBERTS LOONEY其他文献

MARK ROBERTS LOONEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK ROBERTS LOONEY', 18)}}的其他基金

Immunomodulation by splenic megakaryocytes and platelets in sepsis
脓毒症中脾巨核细胞和血小板的免疫调节
  • 批准号:
    10640199
  • 财政年份:
    2022
  • 资助金额:
    $ 45.18万
  • 项目类别:
Immunomodulation by splenic megakaryocytes and platelets in sepsis
脓毒症中脾巨核细胞和血小板的免疫调节
  • 批准号:
    10521976
  • 财政年份:
    2022
  • 资助金额:
    $ 45.18万
  • 项目类别:
Immunobiology of the normal and injured lung
正常和受损肺的免疫生物学
  • 批准号:
    10353875
  • 财政年份:
    2022
  • 资助金额:
    $ 45.18万
  • 项目类别:
Immunobiology of the normal and injured lung
正常和受损肺的免疫生物学
  • 批准号:
    10542751
  • 财政年份:
    2022
  • 资助金额:
    $ 45.18万
  • 项目类别:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
SARS-CoV-2诱导中性粒细胞胞外陷阱的机制和致病性
  • 批准号:
    10490902
  • 财政年份:
    2021
  • 资助金额:
    $ 45.18万
  • 项目类别:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
SARS-CoV-2诱导中性粒细胞胞外陷阱的机制和致病性
  • 批准号:
    10365868
  • 财政年份:
    2021
  • 资助金额:
    $ 45.18万
  • 项目类别:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
SARS-CoV-2诱导中性粒细胞胞外陷阱的机制和致病性
  • 批准号:
    10676842
  • 财政年份:
    2021
  • 资助金额:
    $ 45.18万
  • 项目类别:
Mechanisms of antibody-mediated lung Injury after blood transfusion
输血后抗体介导的肺损伤机制
  • 批准号:
    10318593
  • 财政年份:
    2019
  • 资助金额:
    $ 45.18万
  • 项目类别:
Innate Immune Mechanisms of Primary Graft Dysfunction after Lung Transplantation
肺移植后原发性移植物功能障碍的先天免疫机制
  • 批准号:
    9006789
  • 财政年份:
    2016
  • 资助金额:
    $ 45.18万
  • 项目类别:
Fine-tuning the Neutrophilic Response to Pneumonia
微调中性粒细胞对肺炎的反应
  • 批准号:
    9281669
  • 财政年份:
    2016
  • 资助金额:
    $ 45.18万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
  • 批准号:
    MR/Y000404/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45.18万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了